全文获取类型
收费全文 | 579篇 |
免费 | 24篇 |
国内免费 | 20篇 |
专业分类
儿科学 | 30篇 |
妇产科学 | 22篇 |
基础医学 | 34篇 |
口腔科学 | 10篇 |
临床医学 | 42篇 |
内科学 | 140篇 |
皮肤病学 | 11篇 |
神经病学 | 2篇 |
特种医学 | 101篇 |
外科学 | 77篇 |
综合类 | 8篇 |
预防医学 | 9篇 |
药学 | 105篇 |
中国医学 | 1篇 |
肿瘤学 | 31篇 |
出版年
2023年 | 5篇 |
2022年 | 4篇 |
2021年 | 11篇 |
2020年 | 8篇 |
2019年 | 7篇 |
2018年 | 13篇 |
2017年 | 6篇 |
2016年 | 6篇 |
2015年 | 8篇 |
2014年 | 19篇 |
2013年 | 13篇 |
2012年 | 25篇 |
2011年 | 20篇 |
2010年 | 7篇 |
2009年 | 15篇 |
2008年 | 12篇 |
2007年 | 28篇 |
2006年 | 11篇 |
2005年 | 5篇 |
2004年 | 11篇 |
2003年 | 11篇 |
2002年 | 9篇 |
2001年 | 4篇 |
2000年 | 4篇 |
1999年 | 8篇 |
1998年 | 12篇 |
1997年 | 24篇 |
1996年 | 13篇 |
1995年 | 11篇 |
1994年 | 13篇 |
1993年 | 11篇 |
1992年 | 9篇 |
1991年 | 5篇 |
1990年 | 17篇 |
1989年 | 28篇 |
1988年 | 15篇 |
1987年 | 23篇 |
1986年 | 22篇 |
1985年 | 15篇 |
1984年 | 8篇 |
1983年 | 9篇 |
1982年 | 20篇 |
1981年 | 9篇 |
1980年 | 16篇 |
1979年 | 10篇 |
1978年 | 15篇 |
1977年 | 19篇 |
1976年 | 9篇 |
1975年 | 9篇 |
1974年 | 4篇 |
排序方式: 共有623条查询结果,搜索用时 15 毫秒
11.
Systemic hematologic effects of PEG-rHuMGDF-induced megakaryocyte hyperplasia in mice 总被引:3,自引:3,他引:3
Ulich TR; del Castillo J; Senaldi G; Kinstler O; Yin S; Kaufman S; Tarpley J; Choi E; Kirley T; Hunt P; Sheridan WP 《Blood》1996,87(12):5006-5015
PEG-rHuMGDF injected daily in normal mice causes a rapid dose-dependent increase in megakaryocytes and platelets. At the same time that platelet numbers are increased, the mean platelet volume (MPV) and platelet distribution width (PDW) can be either decreased, normal, or increased depending on the dose and time after administration. Thus, PEG-rHuMGDF at a low dose causes decreases in MPV and PDW, MGDF at an intermediate dose causes an initial increase followed by a decrease in MPV and PDW, and PEG-rHuMGDF at higher doses causes an increase in MPV and PDW followed by a gradual normalization of these platelet indices. In addition to the expected thrombocytosis after 7 to 10 days of daily injection of high doses of PEG-rHuMGDF, a transient decrease in peripheral red blood cell numbers and hemoglobin is noted accompanied in the bone marrow by megakaryocytic hyperplasia, myeloid hyperplasia, erythroid and lymphoid hypoplasia, and deposition of a fine network of reticulin fibers. Splenomegaly, an increase in splenic megakaryocytes, and extramedullary hematopoiesis accompany the hematologic changes in the peripheral blood and marrow to complete a spectrum of pathologic features similar to those reported in patients with myelofibrosis and megakaryocyte hyperplasia. However, all the PEG-rHuMGDF-initiated hematopathology including the increase in marrow reticulin is completely and rapidly reversible upon the cessation of administration of PEG-rHuMGDF. Thus, transient hyperplastic proliferation of megakaryocytes does not cause irreversible tissue injury. Furthermore, PEG-rHuMGDF completely ameliorates carboplatin-induced thrombocytopenia at a low-dose that does not cause the hematopathology associated with myelofibrosis. 相似文献
12.
Oze T Hiramatsu N Song C Yakushijin T Iio S Doi Y Oshita M Hagiwara H Mita E Ito T Inui Y Hijioka T Tamura S Yoshihara H Inoue A Imai Y Hayashi E Kato M Miyazaki M Hosui A Miyagi T Yoshida Y Tatsumi T Kiso S Kanto T Kasahara A Hayashi N Takehara T 《Journal of gastroenterology》2012,47(3):334-342
Background
The timing to the first undetectable hepatitis C virus (HCV) RNA level is strongly associated with sustained virologic response in pegylated interferon (Peg-IFN) plus ribavirin combination therapy for patients with chronic hepatitis C (CH-C) with genotype 1. This study was conducted to clarify the impact of drug exposure to Peg-IFN on the timing of HCV RNA negativity in Peg-IFN plus ribavirin combination therapy for CH-C patients with genotype 1.Methods
A total of 1409 patients treated with Peg-IFN alfa-2b plus ribavirin were enrolled and classified into four categories according to the Peg-IFN dosage. Furthermore, 100 patients were extracted from each Peg-IFN dosage category to adjust for characteristic factors, using the propensity score method.Results
Peg-IFN exposure was dose-dependently associated with the timing of HCV RNA negativity (p????0.001). The HCV RNA negative rate at week 4 decreased from 12% with a Peg-IFN dose of >1.5???g/kg/week to 1?C3% with a dose of <1.5???g/kg/week (p????0.001), and at week 12 the rate had decreased from 44% with a dose of ??1.2???g/kg/week to 18% with a dose of <1.2???g/kg/week (p?=?0.001). Treatment failure (patients without a 1-log decrease of HCV RNA at week 4 or a 2-log decrease of HCV RNA at week 12, or positive at week 24) was found in 54?C66% of patients given <1.2???g/kg/week (p????0.001), and these patients accounted for 64% of the non-responders.Conclusions
The timing of HCV RNA negativity depends significantly on the Peg-IFN dose. Reducing the Peg-IFN dose can induce a later virologic response or non-response in HCV genotype 1 patients treated with Peg-IFN plus ribavirin. 相似文献13.
14.
Masumoto Yoshinobu Fukunishi Shigeo Fukui Tomokazu Yoshiya Shinichi Nishio Shoji Fujihara Yuki Okahisa Shohei Okada Taishi Kanto Makoto Goshi Ariha Morio Futoshi Takeda Yu 《European journal of orthopaedic surgery & traumatology : orthopedie traumatologie》2020,30(3):465-472
European Journal of Orthopaedic Surgery & Traumatology - Combined anteversion (CA) technique (stem-first procedure) is generally accepted as the optimal technique to attain an appropriate CA... 相似文献
15.
Sachiyo Yoshio Tomonari Shimagaki Ryuki Hashida Takumi Kawaguchi Yuriko Tsutsui Yuzuru Sakamoto Yuichi Yoshida Hironari Kawai Shiori Yoshikawa Taiji Yamazoe Taizo Mori Yosuke Osawa Shinji Itoh Moto Fukai Tomoharu Yoshizumi Akinobu Taketomi Masaki Mori Tatsuya Kanto 《Hepatology research》2021,51(7):803-812
16.
17.
Shinichi Kako Yoshinobu Kanda Makoto Onizuka Nobuyuki Aotsuka Kensuke Usuki Takayoshi Tachibana Takeshi Kobayashi Jun Kato Shingo Yano Hiroaki Shimizu Katsuhiro Shono Masatsugu Tanaka Shokichi Tsukamoto Takehiko Mori Etsuko Yamazaki Yuho Najima Akira Hangaishi Takumi Hoshino Reiko Watanabe Kenji Matsumoto Shinichiro Okamoto for Kanto Study Group for Cell Therapy 《American journal of hematology》2020,95(3):251-257
The optimal pre-transplant conditioning for aplastic anemia (AA) remains unclear. We performed a prospective study on allogeneic transplantation from a related or unrelated donor for adult patients with AA. We assessed whether reduced-dose cyclophosphamide (CY) could decrease toxicity while maintaining engraftment, and low-dose thymoglobulin could safely prevent graft-vs-host disease (GVHD). The pre-transplant conditioning regimen consisted of fludarabine 120 mg/m2, CY 100 mg/kg, and thymoglobulin 2.5 mg/kg with or without 2 Gy of total body irradiation. Twenty-seven patients with a median age of 36 years were analyzed. Sixteen patients received graft from related donors. The stem cell source was bone marrow in 26 patients. All of the patients but one, who died early, achieved neutrophil engraftment at a median of 19 days. Mixed chimerism was observed in six and five patients at days 30 and 90, respectively. Only one patient experienced secondary engraftment failure with complete donor-type chimerism. None of the patients developed severe acute GVHD. The cumulative incidence of chronic GVHD was 37.7% at 1 year. The overall survival rate was 96.3% at 1 year and 3 years. A high EB virus-DNA load was detected in one patient at days 60. No one developed EBV-lymphoproliferative disorder within a year. The results suggest that the conditioning regimen in this study was safe and effective. However, relatively high incidence of chronic GVHD needs further improvement. 相似文献
18.
Kelsey E Huntington Anna Louie Lanlan Zhou Attila A Seyhan Aaron WP Maxwell Wafik S El-Deiry 《American journal of cancer research》2022,12(1):138
Tumor cells upregulate myriad proteins that are important for pH regulation, resulting in the acidification of the extracellular tumor microenvironment (TME). Abnormal pH is known to dampen immune function, resulting in a worsened anti-tumor immune response. Understanding how extrinsic alterations in pH modulate the interactions between immune cells and tumors cells will help elucidate opportunities for new therapeutic approaches. We observed that pH impacts the function of immune cells, both natural killer (NK) and T cells, which is relevant in the context of a highly acidic TME. Decreased NK and T cell activity was correlated with decreasing pH in a co-culture immune cell-mediated tumor cell-killing assay. The addition of pH-modulating drugs cariporide, lansoprazole, and acetazolamide to the co-culture assay was able to partially mitigate this dampened immune cell function. Treatment of colorectal cancer (CRC) cells with NHE1 inhibitor cariporide increased CRC cell-secreted cytokines involved in immune cell recruitment and activation and decreased cytokines involved in epithelial-mesenchymal transition (EMT). Cariporide treatment also decreased CRC cell shed TRAIL-R2, TRAIL-R3, and PD-L1 which is relevant in the context of immunotherapy. These experiments can help inform future investigations into how the pH of the tumor microenvironment may be extrinsically modulated to improve anti-tumor immune response in solid tumors such as colorectal cancer. 相似文献
19.
Kohei Yamaguchi Tomomoto Ishikawa Shimpei Mizuta Takumi Takeuchi Hidehiko Matsubayashi Shoji Kokeguchi Toshihiro Habara Kentaro Ichioka Masakazu Ohashi Sumihide Okamoto Toshihiro Kawamura Satoru Kanto Hisanori Taniguchi Fumiko Tawara Tetsuaki Hara Hatsuki Hibi Hiroshi Masuda Takehiko Matsuyama Hiroaki Yoshida 《Reproductive Medicine and Biology》2020,19(2):158-163
20.
Yokota A Ozawa S Masanori T Akiyama H Ohshima K Kanda Y Takahashi S Mori T Nakaseko C Onoda M Kishi K Doki N Aotsuka N Kanamori H Maruta A Sakamaki H Okamoto S;Kanto Study Group for Cell Therapy 《Bone marrow transplantation》2012,47(1):95-100
To evaluate the incidence and risk factors for secondary solid tumors in Japan after allogeneic hematopoietic SCT (allo-HSCT), 2062 patients who had received allo-HSCT between 1984 and 2005 were retrospectively analyzed. Twenty-eight patients who developed 30 solid tumors were identified a median of 5.6 years after transplantation. The risk for developing tumors was 2.16-fold higher than that of the age- and sex-adjusted general population. The cumulative incidence of solid tumors at 10 years after allo-HSCT was 2.4%. The risk was significantly higher for tumors of the skin, oral cavity and esophagus (standard incidental ratio 40.23, 35.25 and 10.73, respectively). No increase in gastric, colon or lung cancer, despite being the most prevalent neoplasm in the Japanese, was observed. In multivariate analysis, occurrence of chronic GVHD and malignant lymphoma as a primary disease was associated with a higher risk for developing solid tumors. Eighteen patients are still alive, and their 5-year probability of survival since diagnosis of solid tumors is 59.7%. Our data suggest that the incidence and risk factors of secondary solid tumors in Japanese allo-HSCT recipients are comparable to those reported in Western countries and emphasize that the early detection of solid tumors has a crucial role in improving OS. 相似文献